Get intelligentvalue.com

Own it today or select a payment plan

Secured by Stripe

Premium Domain Name

intelligentvalue.com

intelligentvalue.com logo

is available for purchase

51 views
Visitors fromUSUS 54%·AUAU 32%·ININ 7%·GBGB 2%·FRFR 2%

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

VisaMastercardAmerican ExpressDiscoverDiners ClubJCBApple PayGoogle Pay

Alpine Immune Sciences to Report Third Quarter 2022 Financial Results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.

Conference Call and Webcast Information

The link to the webcast will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the live event.

About Alpine Immune Sciences

Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.67
+0.97 (0.40%)
AAPL  308.63
+14.25 (4.84%)
AMD  517.82
-23.06 (-4.26%)
BAC  58.73
+0.37 (0.63%)
GOOG  356.18
-1.71 (-0.48%)
META  582.90
-30.01 (-4.90%)
MSFT  390.49
+6.21 (1.62%)
NVDA  194.83
-2.75 (-1.39%)
ORCL  140.27
-2.23 (-1.56%)
TSLA  393.45
-31.85 (-7.49%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.